Carisma Therapeutics Inc. has confirmed that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for their novel product, CT-0525.

MDM2 inhibitors are drugs that target the MDM2 protein, crucial for regulating the tumor suppressor protein p53.

Bio-Thera Solutions has reported encouraging outcomes from its pivotal Phase 3 clinical trial involving BAT2206, a candidate biosimilar for Stelara®.

The definition of IBD in the Guideline refers to the date of the first marketing approval for any product containing the active substance granted to any company in any country in the world.

Halia Therapeutics Reveals Promising Initial Clinical Outcomes for Drug HT-6184 during the Fifth Summit on Inflammasome Treatment Strategies.

NLRP3 inhibitors are drugs that target the NLRP3 inflammasome, a key player in inflammation and immune responses.

OncoResponse, a clinical-stage biotech innovator specializing in immunotherapy derived from elite cancer survivors, announced the first dosing in a Phase 1/2 trial of OR502.

There are two IND categories: Commercial and Research (non-commercial).

Opsidio has initiated dosing of the initial participant in a Phase 2a study evaluating OpSCF for the treatment of moderate to severe eczema.

MAO-B inhibitors are drugs that target the MAO-B enzyme, crucial for regulating neurotransmitters like dopamine.

ASC Therapeutics has reported the inaugural administration to a patient in their Phase I/IIa study for their prime drug, ASC618, conducted at Arkansas Children's Hospital.

There are various types of drug applications submitted to the FDA, including Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Over-the-Counter Drugs (OTC), and Biologic License Application (BLA).